China-NINE Cohort：Neuroimmune Network in Elderly / Neurodegeneration

This is an observational study aimed at understanding the cognitive, functional, and behavioral characteristics of Chinese patients with cognitive impairment, exploring the underlying mechanisms, and providing evidence for early diagnosis, treatment, and care of cognitive disorders including dementia.

Eligible participants will undergo a series of assessments and examinations, including cognitive and memory scale tests, routine blood tests, ApoE genetic testing, cerebrospinal fluid testing, brain MRI, functional MRI, and FDG-PET/AV45-PET scans when necessary. Additional samples such as saliva, nasal secretions, and stool may also be collected. Most evaluations are provided free of charge to support diagnosis and treatment guidance.

Participation is voluntary. All personal information and research data will be kept confidential. Potential benefits include access to expert clinical care and free cognitive assessments for disease evaluation. Possible inconveniences include time commitment and temporary discomfort during examinations; medical support will be provided if needed.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Cognitive Dysfunction Alzheimer Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Cognition Disorders Cognitive Dysfunction, Cognitive Disorder Dementia Mental Disorders Movement Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Parkinson Disease Parkinson's Disease (PD) Parkinsonian Disorders Synucleinopathies Tauopathies

Age range

55 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Yantai Yuhuangding Hospital, Yantai, Shandong, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participants with clinically diagnosed cognitive impairment. Patients with clinically diagnosed Parkinson's disease. Healthy control participants.

Exclusion criteria

Central nervous system infection, head trauma, epilepsy, multiple sclerosis, or other major neurological disorders.

Malignant tumors. Family history of genetic disorders.

Treatment and study plan

Primary outcomes

Degree and Type of Cognitive Impairment Assessed by Neuropsychological Scales

Time frame: From enrollment to the end of treatment at 3 years

Higher scores indicate better cognitive function; lower scores indicate more severe cognitive impairment.

Sponsors and collaborators

Lead sponsor

Yantai Yuhuangding Hospital

Other

Registry information

Important dates

Study start: 2026
Primary completion: 2029
Study completion: 2029
First posted: May 14, 2026
Registry last updated: May 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting